BioFocus, an integrated drug discovery partner, today announced that it has enhanced its diverse screening library through new compound supply agreements with InterBioScreen, Enamine and ChemBridge. BioFocus now offers one of the most powerful screening platforms in the industry with over 900,000 unique chemical compounds and approximately 100,000 probes from natural sources.

Under the agreements BioFocus has selected a total of 350,000 new compounds. These compounds will replace a portion of the current screening library, resulting in a collection with significantly increased novelty, structural diversity and lead likeness, while increasing its overall solubility profile.

“Integrating our screening collection with our assay expertise has provided our clients with a platform that has the size and flexibility to deliver on their hit-finding campaigns”, said Kate Hilyard, Vice President Biological Sciences BioFocus. “This latest round of compound acquisition demonstrates our commitment to maintaining our reputation as a leading partner in drug discovery”.

About BioFocus

BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases and with a growing track record of delivering candidates against rare and neglected diseases.

BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and candidate pre-clinical drugs. The company employs over 220 exceptionally qualified and industry experienced scientists at its three research centers in the UK, Switzerland and the Netherlands.

Since its foundation in 1997, BioFocus has striven to produce high quality data for its clients and this quality is assured by ISO9001 qualification validated by regular, independent inspection of all BioFocus research centers.